Open Access
Performance standards for antimicrobial susceptibility testing
Reads0
Chats0
TLDR
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards.Abstract:
The supplemental information presented in this document is intended for use with the antimicrobial susceptibility testing procedures published in the following Clinical and Laboratory Standards Institute (CLSI)–approved standards: M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition. The standards contain information about both disk (M02) and dilution (M07 and M11) test procedures for aerobic and anaerobic bacteria. Clinicians depend heavily on information from the microbiology laboratory for treatment of their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to provide results for the newest antimicrobial agents. The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most current editions of M02, M07, and M11. Users should replace the tables published earlier with these new tables. (Changes in the tables since the previous edition appear in boldface type.) Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016. The data in the interpretive tables in this supplement are valid only if the methodologies in M02-A12—Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Twelfth Edition; M07-A10—Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Tenth Edition; and M11-A8—Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard— Eighth Edition are followed.read more
Citations
More filters
Journal ArticleDOI
Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients
Alexandre P. Zavascki,Luciano Zubaran Goldani,Guoying Cao,Silvana Superti,Larissa Lutz,Afonso Luis Barth,Fabiano Ramos,Márcio Manozzo Boniatti,Roger L. Nation,Jian Li +9 more
TL;DR: This is the first study to report plasma concentrations over time and urinary recovery of polymyxin B in critically ill patients after intravenous administration, and the total body clearance appears to be relatively insensitive to renal function.
Journal ArticleDOI
Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia
Shelby D. Reed,Joëlle Y. Friedman,John J. Engemann,Robert I. Griffiths,Kevin J. Anstrom,Keith S. Kaye,Martin E. Stryjewski,Lynda A. Szczech,L. Barth Reller,G. Ralph Corey,Kevin A. Schulman,Vance G. Fowler +11 more
TL;DR: Community-dwelling, hemodialysis-dependent patients hospitalized with MRSA bacteremia face a higher mortality risk, longer hospital stays, and higher inpatient costs than do patients with MSSA baiteremia.
Journal ArticleDOI
Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes
Carlota Gudiol,Carlota Gudiol,Fe Tubau,Fe Tubau,Laura Calatayud,Laura Calatayud,Carolina Garcia-Vidal,Carolina Garcia-Vidal,M. Cisnal,Isabel Sánchez-Ortega,R F Duarte,Miguel Calvo,Jordi Carratalà,Jordi Carratalà +13 more
TL;DR: MDRGNB bacteraemia was common among cancer patients, especially in those exposed to antibiotics and urinary catheter, and the most frequent mechanism of resistance was ESBL production.
Journal ArticleDOI
In Vitro Activities of Antibiotics and Antimicrobial Cationic Peptides Alone and in Combination against Methicillin-Resistant Staphylococcus aureus Biofilms
Emel Mataraci,Sibel Döşler +1 more
TL;DR: AMPs seem to be good candidates for further investigations in the treatment of MRSA biofilms, alone or in combination with antibiotics, and use of a combination of antimicrobial agents may help prevent or delay the emergence of resistance.
Journal ArticleDOI
In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria
Akinobu Ito,Takafumi Sato,Merime Ota,Miki Takemura,Toru Nishikawa,Shinsuke Toba,Naoki Kohira,Satoshi Miyagawa,Naoki Ishibashi,Shuhei Matsumoto,Rio Nakamura,Masakatsu Tsuji,Yoshinori Yamano +12 more
TL;DR: Cefiderocol, a novel parenteral siderophore cephalosporin conjugated with a catechol moiety, has a characteristic antibacterial spectrum with a potent activity against a broad range of aerobic Gram-negative bacterial species, including carbapenem-resistant strains of Enterobacteriaceae and nonfermenting bacteria such as Pseudomonas aeruginosa and Acinetobacter baumannii.